Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?
The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.
Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
Insulet Corporation saw a significant drop in stock price in 2023 due to concerns over the impact of GLP-1 weight loss drugs on the insulin pump industry. These fears seem to be largely overblown, however, meaning that Insulet is arguably still trading at a substantial discount to its true value as a company. Insulet's CEO believes that GLP-1 drugs are increasing the adoption of insulin, not decreasing it, suggesting a positive impact on the iCGM industry.
Here's Why Insulet (PODD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
